Cat. No.: HY-13980

UNC0642

27 Cited Publications

Customer Review

Based on 27 publication(s) in Google Scholar

UNC0642, a chemical probe, is a potent and selective lysine methyltransferases G9a and GLP inhibitor, with an IC₅₀ of <2.5 nM for G9a.

For research use only. We do not sell to patients.

Purity: 99.42%
CAS No.: 1481677-78-4
Formula: C₂₉H₄₄F₂N₆O₂
Molecular Weight:546.70

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

UNC0642 Chemical Structure

CAS No.: 1481677-78-4

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (27)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

UNC0642, a chemical probe, is a potent and selective lysine methyltransferases G9a and GLP inhibitor, with an IC₅₀ of <2.5 nM for G9a.

IC₅₀ & Target

EHMT2/G9a/KMT1C

EHMT1/GLP/KMT1D

All Histone Methyltransferase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	1.55 % Compound: UNC0642	Antiproliferative activity against mouse 4T1 cells incubated for 3 to 5 days by MTT assay Antiproliferative activity against mouse 4T1 cells incubated for 3 to 5 days by MTT assay	[PMID: 37788550]
A-375	IC₅₀	3.062 μM Compound: Chemical Probe: UNC0642	Cytotoxicity against human A-375 cells assessed as reduction in cell viability by CCK-8 assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability by CCK-8 assay	[PMID: 32015216]
A-431	IC₅₀	3.38 μM Compound: UNC0642	Antiproliferative activity against human A-431 cells measured after 72 hrs by MTT assay Antiproliferative activity against human A-431 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
CWR22R	GI₅₀	>10 μM Compound: UNC0642	Cytotoxicity against human 22Rv1 cells assessed as growth inhibition measured for 7 days Cytotoxicity against human 22Rv1 cells assessed as growth inhibition measured for 7 days	[PMID: 38602846]
HCT-116	IC₅₀	5.01 μM Compound: UNC0642	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
HeLa	IC₅₀	1.74 μM Compound: UNC0642	Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells measured after 72 hrs by MTT assay	[PMID: 34847495]
HepG2	IC₅₀	2.69 μM Compound: UNC0642	Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
HT-29	IC₅₀	1.35 μM Compound: UNC0642	Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
JJN-3	IC₅₀	17.77 μM Compound: Chemical Probe: UNC0642	Cytotoxicity against human JJN-3 cells expressing shG9a assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay Cytotoxicity against human JJN-3 cells expressing shG9a assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay	[PMID: 32477831]
JJN-3	IC₅₀	18.995 μM Compound: Chemical Probe: UNC0642	Cytotoxicity against human JJN-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human JJN-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 32477831]
JJN-3	IC₅₀	5.85 μM Compound: Chemical Probe: UNC0642	Cytotoxicity against human JJN-3 cells assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay Cytotoxicity against human JJN-3 cells assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay	[PMID: 32477831]
JJN-3	IC₅₀	6.807 μM Compound: Chemical Probe: UNC0642	Cytotoxicity against human JJN-3 cells expressing shNT assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay Cytotoxicity against human JJN-3 cells expressing shNT assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay	[PMID: 32477831]
K562	IC₅₀	0.92 μM Compound: UNC0642	Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
K562	IC₅₀	>10 μM Compound: UNC0642	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 8 days Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 8 days	[PMID: 38602846]
KMS-12-BM	IC₅₀	10.8 μM Compound: Chemical Probe: UNC0642	Cytotoxicity against human KMS-12-BM cells assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay Cytotoxicity against human KMS-12-BM cells assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay	[PMID: 32477831]
KMS-12-BM	IC₅₀	20.255 μM Compound: Chemical Probe: UNC0642	Cytotoxicity against human KMS-12-BM cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human KMS-12-BM cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 32477831]
KMS-12-BM	IC₅₀	23.725 μM Compound: Chemical Probe: UNC0642	Cytotoxicity against human KMS-12-BM cells expressing shNT assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay Cytotoxicity against human KMS-12-BM cells expressing shNT assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay	[PMID: 32477831]
KMS-12-BM	IC₅₀	58.67 μM Compound: Chemical Probe: UNC0642	Cytotoxicity against human KMS-12-BM cells expressing shG9a assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay Cytotoxicity against human KMS-12-BM cells expressing shG9a assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay	[PMID: 32477831]
L02	IC₅₀	3.23 μM Compound: UNC0642	Cytotoxicity against human HL7702 cells measured after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
L02	IC₅₀	6.99 μM Compound: UNC0642	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 2 days by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 37788550]
MDA-MB-231	EC₅₀	16700 nM Compound: 7, UNC0642	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by Alamar Blue assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by Alamar Blue assay	[PMID: 24102134]
MDA-MB-231	IC₅₀	110 nM Compound: 7, UNC0642	Inhibition of lysine methyltransferase G9a in human MDA-MB-231 cells assessed as reduction of H3K9me2 cellular level by immunofluorescence in-cell Western assay Inhibition of lysine methyltransferase G9a in human MDA-MB-231 cells assessed as reduction of H3K9me2 cellular level by immunofluorescence in-cell Western assay	[PMID: 24102134]
MDA-MB-231	IC₅₀	3.23 μM Compound: UNC0642	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay	[PMID: 34847495]
MDA-MB-231	IC₅₀	0.99 μM Compound: UNC0642	Antiproliferative activity against human MDA-MB-231 cells incubated for 3 to 5 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 3 to 5 days by MTT assay	[PMID: 37788550]
MDA-MB-231	IC₅₀	1.003 μM Compound: UNC0642	Antiproliferative activity against human MDA-MB-231 cells after 5 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 5 days by MTT assay	[PMID: 37788550]
MDA-MB-231	IC₅₀	3.31 μM Compound: 3; UNC0642	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 96 hrs by CCK-8 cell viability assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 96 hrs by CCK-8 cell viability assay	[PMID: 39008565]
NCI-H1299	GI₅₀	>10 μM Compound: UNC0642	Cytotoxicity against human NCI-H1299 cells assessed as growth inhibition incubated for 8 days Cytotoxicity against human NCI-H1299 cells assessed as growth inhibition incubated for 8 days	[PMID: 38602846]
PANC-1	EC₅₀	3500 nM Compound: 7, UNC0642	Cytotoxicity against human PANC1 cells after 48 hrs by Alamar Blue assay Cytotoxicity against human PANC1 cells after 48 hrs by Alamar Blue assay	[PMID: 24102134]
PANC-1	IC₅₀	40 nM Compound: 7, UNC0642	Inhibition of lysine methyltransferase G9a in human PANC1 cells assessed as reduction of H3K9me2 cellular level by immunofluorescence in-cell Western assay Inhibition of lysine methyltransferase G9a in human PANC1 cells assessed as reduction of H3K9me2 cellular level by immunofluorescence in-cell Western assay	[PMID: 24102134]
PANC-1	IC₅₀	5.74 μM Compound: 3; UNC0642	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 96 hrs by CCK-8 cell viability assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 96 hrs by CCK-8 cell viability assay	[PMID: 39008565]
PC-3	EC₅₀	8900 nM Compound: 7, UNC0642	Cytotoxicity against human PC3 cells after 48 hrs by Alamar Blue assay Cytotoxicity against human PC3 cells after 48 hrs by Alamar Blue assay	[PMID: 24102134]
PC-3	IC₅₀	130 nM Compound: 7, UNC0642	Inhibition of lysine methyltransferase G9a in human PC3 cells assessed as reduction of H3K9me2 cellular level by immunofluorescence in-cell Western assay Inhibition of lysine methyltransferase G9a in human PC3 cells assessed as reduction of H3K9me2 cellular level by immunofluorescence in-cell Western assay	[PMID: 24102134]
RPMI-8226	IC₅₀	22 μM Compound: Chemical Probe: UNC0642	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability measured after 72 hrs by Celltiter-glo luminescent cell viability assay	[PMID: 32477831]
RPMI-8226	IC₅₀	26.925 μM Compound: Chemical Probe: UNC0642	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 32477831]
U2OS	IC₅₀	130 nM Compound: 7, UNC0642	Inhibition of lysine methyltransferase G9a in human U2OS cells assessed as reduction of H3K9me2 cellular level by immunofluorescence in-cell Western assay Inhibition of lysine methyltransferase G9a in human U2OS cells assessed as reduction of H3K9me2 cellular level by immunofluorescence in-cell Western assay	[PMID: 24102134]
U2OS	EC₅₀	6 μM Compound: 7, UNC0642	Cytotoxicity against human U2OS cells after 48 hrs by Alamar Blue assay Cytotoxicity against human U2OS cells after 48 hrs by Alamar Blue assay	[PMID: 24102134]

In Vitro

UNC0642 displays high in vitro and cellular potency, low cell toxicity, and excellent selectivity. UNC0642 is competitive with the peptide substrate and non-competitive with the cofactor SAM. The K_i of UNC0642 is determined to be 3.7±1 nM. UNC0642 displays high in vitro potency for GLP (IC₅₀< 2.5 nM), similar to G9a. UNC0642 is more than 300-fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion channels. UNC0642 exhibits high potency at reducing the H3K9me2 mark, low cell toxicity, and good separation of functional potency and cell toxicity in a number of cell lines. It reduces clonogenicity in PANC-1 cells, a pancreatic carcinoma cell line^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

A single intraperitoneal (IP) injection (5 mg/kg) of UNC0642 results in a plasma C_max (maximum concentration) of 947 ng/mL and an AUC (area under the curve) of 1265 hr*ng/mL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1481677-78-4
Appearance Solid
Molecular Weight 546.70
Formula C₂₉H₄₄F₂N₆O₂
Color Off-white to light yellow
SMILES

CC(N1CCC(NC2=C3C=C(OC)C(OCCCN4CCCC4)=CC3=NC(N5CCC(F)(F)CC5)=N2)CC1)C
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (27)

All Gel ElectrophoresisBio/Physico-chemical AssayWB

Sort by:

Journal Impact Factor

Nat Cell Biol

Dynamic de novo heterochromatin assembly and disassembly at replication forks ensures fork stability. [Abstract]

2023 Jul;25(7):1017-1032. PMID: 37414849

UNC0642 purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2023 Jul;25(7):1017-1032. [Abstract]

Immunoblot showed pCHK1 levels in wild type cells (WT), wild type where G9a activity was inhibited with UNC0642 (2 h) (WT + UNC0642), and a G9a knock out clone (G9a^-/-), in the presence or in the absence of replication stress.

UNC0642 purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2023 Jul;25(7):1017-1032. [Abstract]

UNC0642 (1 μM; 2 h). Dynamics of H3K9me2 PTM at replication sites in the presence (UNC0642-) or in the absence of G9a activity (UNC0642+) at ongoing (UT) and stalled (HU) replication forks.

UNC0642 purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2023 Jul;25(7):1017-1032. [Abstract]

UNC0642 (1 µM; 2 h) treatment caused TIG3 cells to restart replication more slowly (shorter IdU tracks) than untreated cells after release from HU.
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Cell Death Dis

Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. [Abstract]

2018 Jan 26;9(2):129. PMID: 29374157

UNC0642 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Jan 26;9(2):129. [Abstract]

H3K9Me2, PTEN, p-AKT, and AKT expression levels are measured in PC9/ER xenograft tumor tissues. β-actin is used as a loading control.
Proc Natl Acad Sci U S A

MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. [Abstract]

2019 Feb 19;116(8):2961-2966. PMID: 30718431
Acta Pharmacol Sin

Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells. [Abstract]

2019 Aug;40(8):1076-1084. PMID: 30765842

UNC0642 purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2019 Aug;40(8):1076-1084. [Abstract]

UNC0642 suppresses the activity of G9a protein according to detection of the level of H3K9me2. T24 and J82 cells are treated with UNC0642 for 24 h at the indicated concentration.
Genomics Proteomics Bioinformatics

Integrated Computational and Functional Screening Identify G9a Inhibitors for SETD2-Mutant Leukemia. [Abstract]

2025 Apr 29:qzaf035. PMID: 40300107
Oncogene

BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. [Abstract]

2021 Apr;40(15):2711-2724. PMID: 33712705
Cell Chem Biol

Visualization of the dynamic interaction between nucleosomal histone H3K9 tri-methylation and HP1α chromodomain in living cells. [Abstract]

2022 Jul 21;29(7):1153-1161.e5. PMID: 35728598
J Med Chem

Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. [Abstract]

2024 Sep 12;67(17):15098-15117. PMID: 39145486
Clin Transl Med

Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer. [Abstract]

2024 Jun;14(6):e1692. PMID: 38804602
Ecotoxicol Environ Saf

The critical role of SETDB1-mediated CCND1/PI3K/AKT pathway via p53-RS di-methylation at K370 in the proliferation of WRL68 cells induced by nicotine. [Abstract]

2024 Jul 5:282:116686. PMID: 38971100
J Invest Dermatol

DNA Damage Stress Control Is a Truncated Large T Antigen and Euchromatic Histone Lysine Methyltransferase 2-Dependent Central Feature of Merkel Cell Carcinoma. [Abstract]

2024 Jun 20:S0022-202X(24)01860-8. PMID: 38908781
Cell Prolif

EZH2-mediated inhibition of KLF14 expression promotes HSCs activation and liver fibrosis by downregulating PPARγ. [Abstract]

2021 Jul;54(7):e13072. PMID: 34031939

UNC0642 purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2021 Jul;54(7):e13072. [Abstract]

The HSCs shown were treated with DNMT inhibitors (5-azacytidine, 2 μmol/L), G9a inhibitors (UNC0642, 2 μmol/L), and pan-HDAC inhibitor Givinostat (ITF-2357, 100 nmol/L) for 48 hours, or with EZH2 inhibitors (EPZ-6438, 10 μmol/L) for 72 hours. KLF14 expression was detected by Western blotting.
Int J Mol Sci

Dual Inhibition of H3K9me2 and H3K27me3 Promotes Tumor Cell Senescence without Triggering the Secretion of SASP. [Abstract]

2022 Apr 1;23(7):3911. PMID: 35409271
Cancers (Basel)

Comparative Preclinical Evaluation of BIX-01294 and UNC0642 as EHMT2-Targeting Anticancer Agents. [Abstract]

2026 Apr 15;18(8):1250. PMID: 42073575
iScience

Genome-scale CRISPR-Cas9 screen identifies host factors as potential therapeutic targets for SARS-CoV-2 infection. [Abstract]

2024 Jul 8;27(8):110475. PMID: 39100693
Hum Pathol

The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer. [Abstract]

2018 Feb:72:117-126. PMID: 29133140
Res Sq

2026 Jun 10.
bioRxiv

2026 May 1.
bioRxiv

Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models. [Abstract]

2026 Feb 18:2026.02.16.706212. PMID: 41757027
bioRxiv

EpiBrain: the brain's epigenetic landscape in a snapshot. [Abstract]

2026 Jan 23:2026.01.22.701139. PMID: 41648188
bioRxiv

2025 January 18.
bioRxiv

2024 September 15.
McGill University

2023 Jul.
bioRxiv

2023 Nov 9.
bioRxiv

2023 Nov 17.
bioRxiv

Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models. [Abstract]

2023 Feb 23:2023.02.23.529773. PMID: 36865165

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (91.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8292 mL

9.1458 mL

18.2916 mL

5 mM

0.3658 mL

1.8292 mL

3.6583 mL

10 mM

0.1829 mL

0.9146 mL

1.8292 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

MDA-MB-231, PC3, and U2OS cells are treated with inhibitors (UNC0642) for 48 h. Cell viability assays are performed by incubating cells with 0.1 mg/mL of resazurin for 3 – 4 h. Resazurin reduction is monitored with 544 nm excitation, measuring fluorescence at 590 nm. In-cell western assay is performed as described previously^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice: Standard PK studies are performed using male Swiss albino mice. Plasma and brain concentrations are measured at 0.08, 0.25, 0.5, 1, 2, 4, 8, and 24 h following a single IP injection of UNC0642 at 5 mg/kg. The compound concentration at each time point in plasma or brain is the average value from 3 test animals^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Liu F, et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013 Nov 14;56(21):8931-8942. [Content Brief]

[2]. Wang L, et al. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Cell Death Dis. 2018 Jan 26;9(2):129 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8292 mL	9.1458 mL	18.2916 mL	45.7289 mL
	5 mM	0.3658 mL	1.8292 mL	3.6583 mL	9.1458 mL
	10 mM	0.1829 mL	0.9146 mL	1.8292 mL	4.5729 mL
	15 mM	0.1219 mL	0.6097 mL	1.2194 mL	3.0486 mL
	20 mM	0.0915 mL	0.4573 mL	0.9146 mL	2.2864 mL
	25 mM	0.0732 mL	0.3658 mL	0.7317 mL	1.8292 mL
	30 mM	0.0610 mL	0.3049 mL	0.6097 mL	1.5243 mL
	40 mM	0.0457 mL	0.2286 mL	0.4573 mL	1.1432 mL
	50 mM	0.0366 mL	0.1829 mL	0.3658 mL	0.9146 mL
	60 mM	0.0305 mL	0.1524 mL	0.3049 mL	0.7621 mL
	80 mM	0.0229 mL	0.1143 mL	0.2286 mL	0.5716 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

UNC0642

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Chemical Probe Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) UNC0642

All Histone Methyltransferase Isoforms

Biological Activity

Chemical Information

Publications (27)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

UNC0642

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Chemical Probe Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) UNC0642

All Histone Methyltransferase Isoforms

Biological Activity

Chemical Information

Publications (27)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

UNC0642 Related Classifications

Cat. No.: HY-13980